Angiotensin-converting enzyme (ACE) inhibitors, which prevent the conversion of angiotensin I to II, are well-known for treatments cardiovascular diseases, such as heart failure, hypertension and acute coronary syndrome. Several these inhibitors including captopril, enalapril, ramipril, zofenopril imidapril attenuate vasoconstriction, cardiac hypertrophy adverse remodeling, improve clinical out...

The world faces today a pandemic of unquestionable importance, caused by an infection with new enveloped RNA virus that belongs to the Coronaviridae family. coronavirus (SARS-CoV 2) uses glycoprotein present on its surface bind and infect host cells express angiotensin converting enzyme II (ACE-2). Although different tissues may be targeted virus, respiratory complications remain as main cause ...

background α-adrenergic receptor 2a (adra2a) and angiotensin-converting enzyme (ace) genes have been variably associated with obesity and its related phenotypes in different populations worldwide. objectives this cross-sectional study aims to investigate the association of adrenergic receptor α2a (adra2a) rs553668 and angiotensin-converting enzyme (ace) i/d single nucleotide polymorphisms (snps...

background and aims: diabetic nephropathy (dn) is the most common cause of end-stage renal failure which could increase the risk of cardiovascular disease and morbidity and mortality in patients. the aim of this study was to investigate new modalities for treatment of diabetic nephropathy. methods:this study was a mini-review research to investigate drugs that are used for dn treatment. results...

OBJECTIVES We attempted to compare the effect of an angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) on atherosclerotic events. BACKGROUND Angiotensin-converting enzyme inhibitors and ARBs interrupt the renin-angiotensin system by distinct mechanisms. It is not clear whether ARBs reduce atherosclerotic events such as myocardial infarction (MI) like ACE inhi...

Angiotensin converting enzyme inhibitors are established treatment for hypertension and heart failure. There are well documented differences between ACE inhibitors both in physicochemical properties and pharmacokinetics. Pharmacodynamic actions are similar for most members of the ACE inhibitor class but there are compounds with additional effects which may reflect protease inhibition or non-enz...

The zinc metalloprotease, neprilysin (NEP), plays a role in the metabolism of cardiovascular, inflammatory and neuropeptides, including mitogenic peptides such as bombesin. In the cardiovascular system, NEP has a primary role in the inactivation of natriuretic peptides but also contributes to local metabolism of angiotensin, endothelins and bradykinin. Hence NEP is seen as a potential therapeut...

Activation of the renin-angiotensin system (RAS) is significant in the pathogenesis of cardiovascular disease and specifically coronary atherosclerosis. There is strong evidence that the RAS has effects on the mechanisms of action of atherosclerosis, including fibrinolytic balance, endothelial function, and plaque stability. Pharmacological inhibition of the renin angiotensin system includes an...

Angiotensin converting enzyme (ACE) inhibitors are excellent antihypertensive agents and are becoming widely used as first-line therapy for chronic hypertension in women of reproductive age owing to their efficacy and few side effects. Reports of adverse fetal and neonatal effects from the use of ACE inhibitors in pregnancy in both animal and human studies prompted recommendations against their...

The bioactivity of canary seed peptides (CSP) towards metabolism-regulating enzymes was evaluated. Peptides with angiotensin-converting enzyme (ACE), dipeptidyl peptidase IV (DPP-IV), and pancreatic lipase activity remained stable (p < 0.05) to simulated gastrointestinal digestion (SGD). CSP-SGD were transported efficiently (>10%) through the Caco-2 monolayer, indicating absorption intestinal e...